CN105853380A - Fumaric-acid-tenofovir-dipivoxil tablet and preparing method thereof - Google Patents
Fumaric-acid-tenofovir-dipivoxil tablet and preparing method thereof Download PDFInfo
- Publication number
- CN105853380A CN105853380A CN201610279294.5A CN201610279294A CN105853380A CN 105853380 A CN105853380 A CN 105853380A CN 201610279294 A CN201610279294 A CN 201610279294A CN 105853380 A CN105853380 A CN 105853380A
- Authority
- CN
- China
- Prior art keywords
- parts
- tablet
- tenofovir disoproxil
- disoproxil fumarate
- granule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a fumaric-acid-tenofovir-dipivoxil tablet and a preparing method thereof. The tablet comprises, by weight, 35-50 parts of fumaric acid tenofovir dipivoxil, 30-60 parts of filling agent, 2-10 parts of disintegrating agent, 3-8 parts of bonding agent and 0.1-2 parts of lubricating agent. The experimental result of the tablet shows that the problem that the particle fluidity is poor in the production process of the fumaric-acid-tenofovir-dipivoxil tablet can be well solved through wet pelletizing and particle fluid-bed drying, the preparing method has the advantages of being short in technology process, good in stability and small in pollution in the production process, and is suitable for mass production and application.
Description
Technical field
The invention belongs to field of pharmaceutical preparations, be specifically related to a kind of antiviral drugs tenofovir disoproxil fumarate sheet
Agent and preparation method thereof.
Background technology
The present invention relates to tablet of a kind of antiviral drugs tenofovir disoproxil fumarate (I) and preparation method thereof,
The structural formula of tenofovir disoproxil fumarate is as follows:
Tenofovir disoproxil fumarate (I) is the nucleotide reverse transcription that Gilead sciences company of the U.S. develops
Enzyme inhibitor (nucleotide reverse transcriptase inhibitors, NtRTIs), U.S. FDA is in calendar year 2001
Ratifying its listing, be used for treating acquired immune deficiency syndrome (AIDS) (HIV), (HBV feels for treating chronic hepatitis B within 2008, to ratify again it
Dye).Tenofovir disoproxil fumarate has the features such as better tolerance, resistant rate is low, drug withdrawal rebound rate is low, nephrotoxicity is little, particularly
HIV is merged HBV infection patient there is preferable potential applicability in clinical practice.Tenofovir disoproxil fumarate is tenofovir
Prodrug, due to tenofovir almost without gastrointestinal absorption, so to carry out being esterified, becoming salt to be fumaric acid tenofovir two pyrrole furan
Ester, the latter has water solublity, can be rapidly absorbed and metabolic degradation becomes tenofovir in vivo, play antivirus action.
Chinese patent ZL 98807435.4 describes tenofovir disoproxil fumarate tablet a kind of prescription and
Preparation method.This prescription consumption is: tenofovir disoproxil fumarate 75mg, lactose monohydrate 123.6mg, pregelatinized Starch
11mg, cross-linking sodium carboxymethyl cellulose 8.8mg, magnesium stearate 2.2mg.In this preparation technology, in granule, material is that fumaric acid replaces promise
Good fortune Wei dipivoxil, lactose monohydrate, pregelatinized Starch, cross-linking sodium carboxymethyl cellulose.First this technique carry out wet granulation system
Standby wet granular, wet granular fluid bed drying, the first adjuvant cross-linking sodium carboxymethyl cellulose outer with granule of the granule after drying mixes,
Again mix with magnesium stearate after mix homogeneously, carry out tabletting the most again.Owing to this technique uses twice mixing, operation sequence is multiple
Miscellaneous, workshop energy consumption is big, and the production cycle is long, is unfavorable for big production application.Tenofovir disoproxil fumarate crude drug to high temperature,
High humidity, high temperature and high humidity environment are not the most stable, be not the most stable, easily degrade in formulation process, and generation is replaced
Nuo Fuwei mono-pyrrole furan ester, dimer, mix the impurity such as dimer.The quality of crude drug and medicine system in the production process of medicine
The technique of agent is two important steps determining drug quality, in order to improve the product of tenofovir disoproxil fumarate tablet
Quality, the present invention forms the adjuvant of preparation and preparation technology is studied, on the basis not using special adjuvant and equipment
On, improve storage stability and the dissolution characteristic of tenofovir disoproxil fumarate sheet.
Summary of the invention
The invention provides a kind of tenofovir disoproxil fumarate tablet, crude drug is fumaric acid tenofovir two pyrrole
Furan ester, adjuvant is filler, disintegrating agent, binding agent, lubricant.This oral solid tablet is made up of the material of following weight parts:
35～50 parts of tenofovir disoproxil fumarates, the filler of 30～60 parts, the disintegrating agent of 2～10 parts, 3～8
The binding agent of part, the lubricant composition of 0.1～2 part, granule uses wet granulation, fluid bed drying granule, is dried pellet moisture
Control to be not more than 2.0%.
Wherein:
Described filler is: lactose monohydrate and two kinds of adjuvants of microcrystalline Cellulose, both each shared weight portion be all higher than
Zero；
Disintegrating agent is: cross-linking sodium carboxymethyl cellulose；
Binding agent is: pregelatinized Starch；
Lubricant is: magnesium stearate.
A kind of adjuvant may play multiple effect in same tablet, and without filler, disintegrating agent, binding agent, lubrication
Agent limits its single effect in tablets.
The invention provides a kind of tenofovir disoproxil fumarate oral solid tablet, this tablet is preferably by following
The material of weight portion is made:
Tenofovir disoproxil fumarate 38～48 parts
Lactose monohydrate 28～38 parts
Microcrystalline Cellulose 8～15 parts
Cross-linking sodium carboxymethyl cellulose 4～8 parts
Pregelatinized Starch 4～7 parts
Magnesium stearate 0.5～1.5 parts.
The invention provides a kind of tenofovir disoproxil fumarate oral solid tablet, be more specifically this tablet
It is made up of the material of following weight parts:
Tenofovir disoproxil fumarate 43.2 parts
Lactose monohydrate 33.3 parts
Microcrystalline Cellulose 11.6 parts
Cross-linking sodium carboxymethyl cellulose total amount 6.0 parts
Wherein (1) intra-particle crosslink sodium carboxymethyl cellulose 2.0 parts
(2) extragranular connection sodium carboxymethyl cellulose 4.0 parts
Pregelatinized Starch 4.9 parts
Magnesium stearate 1.0 parts.
In tenofovir disoproxil fumarate tablet, add microcrystalline Cellulose can improve the character of compressed tablet.Crystallite
Cellulose has hygroscopy, and its water capacity is the lowest, and it is when relative humidity is 60%, and equilibrium moisture content is own wt
6%, therefore both it was difficult to the moisture absorption with its tablet made, again can rapid disintegrate in water or in stomach.
The invention provides a kind of tenofovir disoproxil fumarate tablet, this tablet can be thin with stomach dissolution type further
Film coating pre-mixing agent aqueous solution, as Shanghai Ka Lekang packaging technique company limited containing indigo aluminum color lake 2, hydroxypropyl first fiber
2910, lactose, titanium dioxide, the stomach dissolved film coating pre-mix dose aqueous solution system of glyceryl triacetate are prepared as coated tablet,
Under high temperature and high humidity, tenofovir disoproxil fumarate tablet stability is poor, and this film coating can be protected effectively
Bluff piece core, improves the stability of tenofovir disoproxil fumarate.Stomach dissolution type coating membrane ruptures under the effect of gastric juice, rich horse
Acid tenofovir dipivoxil is rapidly absorbed, and is degraded the most in vivo, phosphoric acid chemical conversion diphosphonic acid tenofovir, plays disease-resistant
Toxic action.
The invention provides a kind of tenofovir disoproxil fumarate oral solid tablet preparation method, it is characterised in that
In granule, part uses wet granulation, fluid bed drying granule, carries out according to the steps:
(1) pelletize: by tenofovir disoproxil fumarate, lactose monohydrate, microcrystalline Cellulose, intra-particle crosslink carboxymethyl
Sodium cellulosate, pregelatinized Starch mix homogeneously, addition water is as wetting agent, and stir in granulator formation wet granular；
(2) being dried: use pressure spray process dry wet particle at the bottom of fluid bed, wet granular puts into fluid bed, opens fluid bed, control
Inlet temperature processed is between 40-80 DEG C, and regulation air quantity makes material be in fluidized state, and is that 1.00mm screen cloth midway is whole with aperture
Grain, continuation fluid bed drying is not more than 2.0% to pellet moisture afterwards；
(3) granulate: the granule aperture of moisture no more than 2.0% is 1.00mm screen cloth granulate again；
(4) mixing: dried granule adjuvant cross-linking sodium carboxymethyl cellulose outer with granule, magnesium stearate mix homogeneously；
(5) tabletting: mixed granule carries out pressing element sheet.
Element sheet can coating further:
(6) coating: element sheet Shanghai Ka Lekang packaging technique company limited containing indigo aluminum color lake 2, hydroxypropyl first is fine
Dimension element 2910, lactose, titanium dioxide, the stomach dissolved film coating pre-mix dose aqueous solution of glyceryl triacetate is coated.
Wherein the consumption of wetting agent water is the 35%～45% of total tablet weight.
Wherein pellet moisture measures and uses moisture teller.
The dissolution test of this product tablet: carry out with reference to Chinese Pharmacopoeia 2015 editions, uses paddle method, and temperature is 37 DEG C, with
0.1mol/L hydrochloric acid solution 900ml is dissolution medium, and rotating speed is 50 turns per minute, operates in accordance with the law, through 30 minutes time, takes solution
10ml, filters, and precision measures subsequent filtrate 1ml, puts in 20ml measuring bottle, adds 0.1mol/L hydrochloric acid solution and is diluted to scale, shakes up, and makees
For need testing solution.Separately take tenofovir disoproxil fumarate reference substance appropriate, accurately weighed, add 0.1mol/L hydrochloric acid solution
Dissolve and quantitatively dilution makes the solution in every 1ml containing about 16 μ g, as reference substance solution.Take above two solution, according to ultraviolet-
Visible spectrophotometry, measures absorbance at the wavelength of 260nm respectively, calculates the stripping quantity of every.Experiment shows: several places
The preparation stripping curve that side's technique prepares and fumaric acid tenofovir two pyrrole described in patent ZL 98807435.4
Tablet stripping curve prepared by furan ester prescription and technique is similar.
Tenofovir disoproxil fumarate sheet solid preparation disclosed by the invention and prior art patent ZL
98807435.4 compare have the advantage that is: label adjuvant adds microcrystalline Cellulose, and adjuvant outer with granule mixes once to enter
OK, operation sequence is few, pollutes little in production process.Fluid bed drying wet granular, efficiency is high, and simple to operate, mobility of particle is good.
Whole stable technical process is good, has related substance, crystal formation etc. not to change, good stability in prolonged storage.The most molten
Go out curve comparison research display, the self-control preparation prepared by prescription and the technique of the present invention with according to patent ZL
Tablet prepared by tenofovir disoproxil fumarate tablet recipe described in 98807435.4 and technique can be in 15min
Dissolution reaches more than 85%, and stripping curve is similar.
Accompanying drawing illustrates:
Fig. 1 be embodiment 1 (lot number 01150301) Accumulation dissolution stripping curve with according in patent ZL 98807435.4
Tablet (lot number 13VR066D) stripping curve contrast prepared by the tenofovir disoproxil fumarate tablet recipe described and technique
Result.
Fig. 2 be embodiment 2 (lot number 01150302) Accumulation dissolution stripping curve with according in patent ZL 98807435.4
Tablet (lot number 13VR066D) stripping curve contrast prepared by the tenofovir disoproxil fumarate tablet recipe described and technique
Result.
Fig. 3 be embodiment 3 (lot number 01150303) Accumulation dissolution stripping curve with according in patent ZL 98807435.4
Tablet (lot number 13VR066D) stripping curve contrast prepared by the tenofovir disoproxil fumarate tablet recipe described and technique
Result.
Detailed description of the invention
The present invention is to be described by the following specific embodiments, can be better understood from this by specific embodiment
Bright, but the scope of the present invention is not restricted by the embodiments:
Embodiment 1:
Tenofovir disoproxil fumarate tablet (wet granulation technology)
Prescription:
Technique:
By tenofovir disoproxil fumarate 300g, cross-linking sodium carboxymethyl cellulose 13.6g, lactose monohydrate 231.2g,
Microcrystalline Cellulose 80.8g, pregelatinized Starch 34g put into granulator, crude drug and adjuvant and stir 3 minutes.
Pelletize: add wetting agent purified water 265g, pelletize and obtain wet granular in 2 minutes.
It is dried: fluid bed drying intake air temperature 40 DEG C～80 DEG C, is 1.00mm screen cloth midway granulate with aperture, after granulate
Continuation fluid bed drying, to moisture≤2.0%, is finally 1.00mm screen cloth granulate with aperture, receives granule 659g.
Mixing: the dried granule of gained and additional adjuvant 26.4g cross-linking sodium carboxymethyl cellulose and 6.6g magnesium stearate
Mix homogeneously.
Tabletting: pressure element sheet.
Coating: with Shanghai Ka Lekang packaging technique company limited containing indigo aluminum color lake 2, hydroxypropyl methylcellulose
2910, lactose, titanium dioxide, the stomach dissolved film coating pre-mix dose aqueous solution bag element sheet of glyceryl triacetate, obtain fumaric acid
Tenofovir dipivoxil sheet.
Fig. 1 be embodiment 1 (lot number 01150301) Accumulation dissolution stripping curve with according in patent ZL 98807435.4
Tablet (lot number 13VR066D) stripping curve contrast prepared by the tenofovir disoproxil fumarate tablet recipe described and technique
Result.
Embodiment 2:
Tenofovir disoproxil fumarate tablet (wet granulation technology)
Prescription:
Technique:
By tenofovir disoproxil fumarate 300g, cross-linking sodium carboxymethyl cellulose 13.5g, lactose monohydrate 218.0g,
Microcrystalline Cellulose 75g, pregelatinized Starch 50g put into granulator, crude drug and adjuvant and stir 3 minutes.
Pelletize: add wetting agent purified water 250g, pelletize and obtain wet granular in 5 minutes.
It is dried: fluid bed drying intake air temperature 40 DEG C～80 DEG C, is 1.00mm screen cloth midway granulate with aperture, after granulate
Continuation fluid bed drying, to moisture≤2.0%, is finally 1.00mm screen cloth granulate with aperture, receives granule 589g.
Mixing: the dried granule of gained and additional adjuvant 11.8g cross-linking sodium carboxymethyl cellulose and 8.8g magnesium stearate
Mix homogeneously.
Tabletting: pressure element sheet.
Coating: with Shanghai Ka Lekang packaging technique company limited containing indigo aluminum color lake 2, hydroxypropyl methylcellulose
2910, lactose, titanium dioxide, the stomach dissolved film coating pre-mix dose aqueous solution bag element sheet of glyceryl triacetate, obtain fumaric acid
Tenofovir dipivoxil sheet.
Fig. 2 be embodiment 2 (lot number 01150302) Accumulation dissolution stripping curve with according in patent ZL 98807435.4
Tablet (lot number 13VR066D) stripping curve contrast prepared by the tenofovir disoproxil fumarate tablet recipe described and technique
Result.
Embodiment 3:
Tenofovir disoproxil fumarate tablet (wet granulation technology)
Prescription:
Technique:
By tenofovir disoproxil fumarate 300g, cross-linking sodium carboxymethyl cellulose 13.6g, lactose monohydrate 226.44g,
Microcrystalline Cellulose 75.48g, pregelatinized Starch 44.06g put into granulator, crude drug and adjuvant and stir 3 minutes.
Pelletize: add wetting agent purified water 283g, pelletize and obtain wet granular in 3 minutes.
It is dried: fluid bed drying intake air temperature 40 DEG C～80 DEG C, is 1.00mm screen cloth midway granulate with aperture, after granulate
Continuation fluid bed drying, to moisture≤2.0%, is finally 1.00mm screen cloth granulate with aperture, receives granule 556g.
Mixing: the dried granule of gained and additional adjuvant 11.1g cross-linking sodium carboxymethyl cellulose and 5.6g magnesium stearate
Mix homogeneously.
Tabletting: pressure element sheet.
Coating: with Shanghai Ka Lekang packaging technique company limited containing indigo aluminum color lake 2, hydroxypropyl methylcellulose
2910, lactose, titanium dioxide, the stomach dissolved film coating pre-mix dose aqueous solution bag element sheet of glyceryl triacetate, obtain fumaric acid
Tenofovir dipivoxil sheet.
Fig. 3 be embodiment 3 (lot number 01150303) Accumulation dissolution stripping curve with according in patent ZL 98807435.4
Tablet (lot number 13VR066D) stripping curve contrast prepared by the tenofovir disoproxil fumarate tablet recipe described and technique
Result.
Embodiment 4: stability test
Sheet is prepared with reference to the tenofovir disoproxil fumarate method for preparing tablet thereof in Chinese patent ZL 98807435.4
Agent a collection of (lot number: 13VR066D) and the present invention make preparation (embodiment 1: lot number 01150301 by oneself；Embodiment 2: lot number
01150302；Embodiment 3: lot number 01150303) coated tablet uses same inner packing, and at temperature 60 C, humidity 75%RH is examined
Having examined 10 days, result display self-control tablet ratio is with reference to the fumaric acid tenofovir two pyrrole furan in Chinese patent ZL 98807435.4
It is good that ester method for preparing tablet thereof prepares tablet stability, and impurity growth rate is slow, and total impurities is few, and storage stability is better than in reference
Tablet prepared by the tenofovir disoproxil fumarate method for preparing tablet thereof in state's patent ZL 98807435.4.
Study on the stability experiment condition: temperature 60 C, humidity 75%RH, the investigation time: 10 days.Result see table:
Impurity D: Tenofovir
Impurity F: O-isopropyl Tenofovir
Impurity S: mixing dimer
Impurity H: dimer
Above-described embodiment is the present invention preferably embodiment, but embodiments of the present invention are not by above-described embodiment
Limit, the change made under other any spirit without departing from the present invention and principle, modify, substitute, combine, simplify,
All should be equivalent replacement mode, within being included in protection scope of the present invention.
Claims (10)
1. an antiviral drugs tenofovir disoproxil fumarate tablet, it is characterised in that this tablet is by following weight parts
Material is made:
The tenofovir disoproxil fumarate of 35～50 parts, the filler of 30～60 parts, the disintegrating agent of 2～10 parts, 3～8 parts
Binding agent, the lubricant of 0.1～2 part, granule use wet granulation, fluid bed drying granule, be dried pellet moisture control not
More than 2.0%；
Described filler is selected from: one or both in lactose monohydrate or microcrystalline Cellulose；
Disintegrating agent is: cross-linking sodium carboxymethyl cellulose；
Binding agent is: pregelatinized Starch；
Lubricant is: magnesium stearate.
Tenofovir disoproxil fumarate tablet the most according to claim 1, it is characterised in that described filler is
Lactose monohydrate and two kinds of adjuvants of microcrystalline Cellulose, both each shared parts by weight be all higher than zero.
Tenofovir disoproxil fumarate tablet the most according to claim 1, it is characterised in that described disintegrating agent is
Cross-linking sodium carboxymethyl cellulose.
Tenofovir disoproxil fumarate tablet the most according to claim 1, it is characterised in that described binding agent is
Pregelatinized Starch.
Tenofovir disoproxil fumarate tablet the most according to claim 1, it is characterised in that described lubricant is
Magnesium stearate.
6. according to the tenofovir disoproxil fumarate oral solid tablet one of claim 1-5 Suo Shu, it is characterised in that
This tablet is made up of the material of following weight parts:
Tenofovir disoproxil fumarate 38～48 parts
Lactose monohydrate 28～38 parts
Microcrystalline Cellulose 8～15 parts
Cross-linking sodium carboxymethyl cellulose 4～8 parts
Pregelatinized Starch 4～7 parts
Magnesium stearate 0.5～1.5 parts.
7. according to the tenofovir disoproxil fumarate oral solid tablet one of claim 1-5 Suo Shu, it is characterised in that
This tablet is made up of the material of following weight parts:
Tenofovir disoproxil fumarate 43.2 parts
Lactose monohydrate 33.3 parts
Microcrystalline Cellulose 11.6 parts
Cross-linking sodium carboxymethyl cellulose total amount 6.0 parts
Wherein (1) intra-particle crosslink sodium carboxymethyl cellulose 2.0 parts
(2) extragranular connection sodium carboxymethyl cellulose 4.0 parts
Pregelatinized Starch 4.9 parts
Magnesium stearate 1.0 parts.
8. the preparation method of the tenofovir disoproxil fumarate tablet of one of claim 1-7, it is characterised in that in granule
Part uses wet granulation, fluid bed drying granule, carries out according to the steps:
(1) pelletize: by tenofovir disoproxil fumarate, lactose monohydrate, microcrystalline Cellulose, intra-particle crosslink carboxymethyl cellulose
Element sodium, pregelatinized Starch mix homogeneously, addition water is as wetting agent, and stir in granulator formation wet granular；
(2) being dried: use pressure spray process dry wet particle at the bottom of fluid bed, wet granular puts into fluid bed, opens fluid bed, control into
Air temperature is between 40-80 DEG C, and regulation air quantity makes material be in fluidized state, and is 1.00mm screen cloth midway granulate with aperture,
Continuation fluid bed drying is not more than 2.0% to pellet moisture afterwards；
(3) granulate: the granule aperture of moisture no more than 2.0% is 1.00mm screen cloth granulate again；
(4) mixing: dried granule adjuvant cross-linking sodium carboxymethyl cellulose outer with granule, magnesium stearate mix homogeneously；
(5) tabletting: mixed granule carries out pressing element sheet.
The preparation method of tenofovir disoproxil fumarate tablet the most according to claim 8, it is characterised in that moistening
The consumption of agent water is the 35%～45% of total tablet weight.
The preparation method of tenofovir disoproxil fumarate tablet the most according to claim 8 or claim 9, it is characterised in that
This tablet is stomach dissolution type thin membrane coated tablet, and after pressure element sheet, element sheet stomach dissolved film coating pre-mix dose aqueous solution wraps
Clothing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610279294.5A CN105853380A (en) | 2016-04-29 | 2016-04-29 | Fumaric-acid-tenofovir-dipivoxil tablet and preparing method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610279294.5A CN105853380A (en) | 2016-04-29 | 2016-04-29 | Fumaric-acid-tenofovir-dipivoxil tablet and preparing method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105853380A true CN105853380A (en) | 2016-08-17 |
Family
ID=56630139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610279294.5A Pending CN105853380A (en) | 2016-04-29 | 2016-04-29 | Fumaric-acid-tenofovir-dipivoxil tablet and preparing method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105853380A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108096206A (en) * | 2018-02-01 | 2018-06-01 | 海南天煌制药有限公司 | A kind of tenofovir disoproxil fumarate tablet and preparation method thereof |
| CN108464972A (en) * | 2018-07-02 | 2018-08-31 | 福州大学 | A kind of anti-pulmonary hypertension oral tablet and preparation method thereof containing Snopori |
| CN111939134A (en) * | 2020-08-24 | 2020-11-17 | 山东罗欣药业集团股份有限公司 | Antiviral medicine composition |
| CN117338733A (en) * | 2023-10-12 | 2024-01-05 | 杭州和泽坤元药业有限公司 | Tenofovir disoproxil fumarate tablet and preparation process thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009106954A1 (en) * | 2008-02-27 | 2009-09-03 | Aurobindo Pharma Limited | Stable dosage forms of lamivudine and tenofovir |
| CN103830192A (en) * | 2012-11-27 | 2014-06-04 | 安徽贝克生物制药有限公司 | Tenofovir disoproxil fumarate tablets allowing direct powder compression and preparation method thereof |
| CN104288118A (en) * | 2014-07-08 | 2015-01-21 | 南京卡文迪许生物工程技术有限公司 | Tenofovir disoproxil fumarate tablet and preparation method thereof |
| CN105213332A (en) * | 2014-06-17 | 2016-01-06 | 广州朗圣药业有限公司 | Oral tablet of a kind of tenofovir disoproxil fumarate and preparation method thereof |
-
2016
- 2016-04-29 CN CN201610279294.5A patent/CN105853380A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009106954A1 (en) * | 2008-02-27 | 2009-09-03 | Aurobindo Pharma Limited | Stable dosage forms of lamivudine and tenofovir |
| CN103830192A (en) * | 2012-11-27 | 2014-06-04 | 安徽贝克生物制药有限公司 | Tenofovir disoproxil fumarate tablets allowing direct powder compression and preparation method thereof |
| CN105213332A (en) * | 2014-06-17 | 2016-01-06 | 广州朗圣药业有限公司 | Oral tablet of a kind of tenofovir disoproxil fumarate and preparation method thereof |
| CN104288118A (en) * | 2014-07-08 | 2015-01-21 | 南京卡文迪许生物工程技术有限公司 | Tenofovir disoproxil fumarate tablet and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 杜艺伟，等: "富马酸替诺福韦二吡呋酯片处方开发研究", 《中国医药科学》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108096206A (en) * | 2018-02-01 | 2018-06-01 | 海南天煌制药有限公司 | A kind of tenofovir disoproxil fumarate tablet and preparation method thereof |
| CN108464972A (en) * | 2018-07-02 | 2018-08-31 | 福州大学 | A kind of anti-pulmonary hypertension oral tablet and preparation method thereof containing Snopori |
| CN111939134A (en) * | 2020-08-24 | 2020-11-17 | 山东罗欣药业集团股份有限公司 | Antiviral medicine composition |
| CN111939134B (en) * | 2020-08-24 | 2023-02-17 | 山东罗欣药业集团股份有限公司 | Antiviral medicine composition |
| CN117338733A (en) * | 2023-10-12 | 2024-01-05 | 杭州和泽坤元药业有限公司 | Tenofovir disoproxil fumarate tablet and preparation process thereof |
| CN117338733B (en) * | 2023-10-12 | 2024-05-28 | 杭州和泽坤元药业有限公司 | Tenofovir disoproxil fumarate tablet and preparation process thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5278708B2 (en) | Nateglinide-containing hydrophilic pharmaceutical formulation | |
| CN106102716A (en) | The solid composite medicament of androgen receptor antagonists | |
| CN105853380A (en) | Fumaric-acid-tenofovir-dipivoxil tablet and preparing method thereof | |
| CA2813147A1 (en) | Preparation for improving solubility of poorly soluble drug | |
| CN106924208A (en) | A kind of compound Dapagliflozin Metformin Extended-release Tablets and preparation method thereof | |
| CN105640913B (en) | A kind of olmesartan medoxomil tablet and preparation method thereof | |
| CN102008449B (en) | Lansoprazole enteric pellet and preparation method thereof | |
| CN104873473A (en) | Potassium chloride sustained-release tablet and preparation method thereof | |
| CN103254174A (en) | Lansoprazole compound and pharmaceutical composition thereof | |
| CN104434826B (en) | A kind of Rosuvastatin calcium dispersible tablet | |
| WO2023213878A1 (en) | Solid tablet dosage form of ridinilazole | |
| CN113633616A (en) | Solid preparation with high bioavailability | |
| US20220226249A1 (en) | Solid tablet dosage form of ridinilazole | |
| CN106511291A (en) | Acotiamide hydrochloride controlled release tablet and preparation method thereof | |
| CN102885774B (en) | Prasugrel composition and preparation method thereof | |
| CN101385717B (en) | Solid dispersion containing sofalcone as active ingredient and preparation method thereof | |
| CA3094551C (en) | Extended release pharmaceutical composition containing fesoterodine and process for the preparation thereof | |
| CN105902564A (en) | Pharmaceutical composition for treating hypertension and preparation method thereof | |
| CN105534980B (en) | The pharmaceutical composition and its preparation process of Repaglinide Metformin hydrochloride | |
| CN109985013B (en) | Nitrendipine dispersible tablet and preparation method thereof | |
| CN104000821B (en) | Oral double-layer tablet containing telmisartan and amlodipine besylate and preparation method thereof | |
| CN109700778B (en) | Cinacalcet hydrochloride quick-release preparation and preparation method thereof | |
| CN108159053A (en) | A kind of pharmaceutical composition containing Cefditoren pivoxil Cephalosporins | |
| US20050215455A1 (en) | Surfactants in powdered form that can be used in tablets or gelatin capsules; preparation process and compositions containing them | |
| JP6668666B2 (en) | Pharmaceutical composition containing irbesartan and method for producing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160817 |
|
| RJ01 | Rejection of invention patent application after publication |